Femara
Femara is indicated for the treatment of hormone-dependent breast cancer and utilized to alleviate tumour growth in post-menopausal women.
Strengths: 2.5mg
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Aromatase Inhibitor
- Pharmacological class
Aromatase Inhibitor
- Known off-label uses
infertility
- Contraindications
pre-menopausal status; pregnancy; breastfeeding; hypersensitivity to letrozole
- Minor side effects
hot flushes; fatigue; hypercholesterolaemia
- Moderate side effects
joint pain; nausea; osteoporosis; alopecia
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Novartis
- Onset Time
2–4 weeks
- Duration
24 hours
- Storage instructions
Store below 30°C, keep dry.
- Drug interactions
Tamoxifen; Oestrogen based supplements
- Age restrictions
Strictly for post-menopausal women.
- Pregnancy and breastfeeding
Pregnancy: Contraindicated. Breastfeeding: Contraindicated.
Precautions and warnings
monitor bone health; use with caution in moderate renal impairment; avoid if hepatic impairment is severe
Serious side effects
fractures — requires immediate medical attention; angina pectoris — requires immediate medical attention; myocardial infarction — requires immediate medical attention
Patient summary
Femara is indicated for the treatment of hormone-dependent breast cancer and utilized to alleviate tumour growth in post-menopausal women.
Mechanism of action
As a potent non-steroidal aromatase inhibitor, it effectively blocks the production of oestrogen by inhibiting the aromatase enzyme, which leads to a significant decrease in serum oestrogen levels, thus slowing the growth of sensitive cancer cells.
Femara
Femara is indicated for the treatment of hormone-dependent breast cancer and utilized to alleviate tumour growth in post-menopausal women.
Editorial Notes
- Active ingredient(s): Letrozole
- Listed indication(s): Breast Cancer
Available option
- 120 tablets - 2.5 mg469-2-5-mg-1116